Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Macular Diseases

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

J Clin Med

Teper S, Ledwoń D, Romaniszyn-Kania P, Sendecki A, Tuszy A, Nycz J, Mitas AW, Figurska M, Wylęgała E, Rękas M

doi: 10.3390/jcm14196771

Retinal DiseasesFurther Publications

Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data

Retina

Chhablani J, Nayaka A, Sadeghi E, B G

doi: 10.1097/IAE.0000000000004980

Macular DiseasesRetinal Diseases

Longitudinal Changes in Inner Retinal Layers in Treatment-Naïve Neovascular AMD During Intravitreal Anti-VEGF Therapy

Ophthalmol Retina

Kardo H, Garweg RA, Imbach L, Garweg JG

doi: 10.1016/j.oret.2026.08.031

Macular Diseases

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Retina

Lee C, Karunainathan MG, Zohalinejad KD, Mæng MO, Fabrin NW, Yde SK, Wykoff CC, Abildgaard SK, Vorum H, Subhi Y, Ørskov M, Cehofski LJ

doi: 10.1097/IAE.0000000000004888

Macular Diseases

Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data

Acta Ophthalmol

Karunainathan MG, Lee C, Zohalinejad KD, Mæng MO, Fabrin NW, Jónsdóttir S, Hassing AK, Yde SK, Wykoff CC, Vorum H, Subhi Y, Ørskov M, Cehofski LJ

doi: 10.1111/aos.70160

Macular Diseases

Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema

Am J Ophthalmol

Kundu R, Goturi N, Green M, Poulaki V, Siegel NH, Subramanian ML, Ness S

doi: 10.1016/j.ajo.2026.09.002

Retinal Diseases

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

J Clin Med

Rodríguez-Fernández CA, Oliver-Gutierrez D, Arnaiz A, Pablos T, Segura-Duch G, Zapata MÁ

doi: 10.3390/jcm15124508

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular Diseases

Long-term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

Acta Ophthalmol

Teper S, Ledwoń D, Sendecki A, Romaniszyn-Kania P, Tuszy A, Nycz J, Mitas AW, Figurska M, Wylęgała E, Rękas M

doi: 10.1111/aos.70040

Related content

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data

Longitudinal Changes in Inner Retinal Layers in Treatment-Naïve Neovascular AMD During Intravitreal Anti-VEGF Therapy

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data

Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Long-term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry